Carnot CALYM

The Consortium for the acceleration of innovation and its transfer in the lymphoma field

The CALYM Carnot Institute brings together 15 research teams specialized in lymphoma, first blood cancer.

This academic consortium, without international equivalent, aims at accelerating innovation and its transfer in the lymphoma treatment and diagnosis through a unique R&D offering: from the identification of new biological targets to registration clinical trials.

Competences

Core business

Health
Technologies for health
Key figures
Fermer

Key figures

Permanent staff (full-time equivalent)
246
including PhD Students
32
Global budget
33,5 M€
Partnership
incomes with industry
20,17 M€
Contact
Fermer

Contact

institut Carnot CALYM
LYSARC
Centre Hospitalier Lyon-Sud
Secteur Sainte Eugénie
Pavillon 6E
69495  Pierre-Bénite Cedex

Bertrand NADEL
Director
+33(0)4 72 24 41 71
+33(0)7 63 79 13 40

Email contact

Presentation

A Carnot Institute Devoted to Lymphoma: Creating Synergies, Initiating Partnerships, Accelerating Translational Research

Consortium overview 

15 multidisciplinary and complementary research entities in the lymphoma field:
  • LYSA: The Lymphoma Study Association, a cooperative group
  • LYSARC: The Lymphoma Academic Research Organisation
  • 13 academic research teams (belonging to Inserm or CNRS national research bodies, to universities and/or to hospitals)
  • CALYM is member of FINDMED
    www.findmed.fr

Our 4 R&D Pillars at the Core of Innovation

  1. Research and validation of new biological targets and lymphoma in vitro and in vivo models
    > to develop new preclinical drug candidates
  2. Identification, validation, patenting and licensing of blood and tissue biomarkers
    > to improve diagnosis, guide therapy decisions and predict tumor responses
  3. Early monitoring of activity (early pharmacodynamic markers, circulating DNA, immunomonitoring)
    > to accelerate translational research
  4. Optimization and exploitation of clinical research related tools
    > to accelerate development, registration and market access of drug candidates

                       

Our Platforms and Technical Resources

  • CALYM offers various terms of collaboration covering all stages of R&D :

       • contract research partnerships on preclinical, translational or clinical (multicenter) projects
       • joint setting-up of projects on national or international calls for projects
       • access to its databases, technical platforms, biological collections, preclinical models, technical resources
       • expertise and consulting of internationally renowned lymphoma experts
 

  • CALYM is certified ISO 9001:2015 for the management and monitoring of its research activities